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ABSTRACT 
This record of study details the experience and the knowledge applied by an 
engineering doctoral candidate during two internships with two separate organizations in 
the cardiovascular device industry. The first internship was with an early startup 
company with a large focus in early research and design. The second was in a more 
mature organization with a focus in process control and increasing efficiencies. 
The startup company provided the appropriate dynamic for applying engineering 
design methods such as generating customer requirements, generating product functional 
requirements, building a quality function deployment, and proposing a basic high level 
design approach. With the mature company the focus was on investigating procedural 
inefficiencies through root cause analysis and mitigating the inefficiencies through 
integrated software solutions. 
The detailed accounts of these experiences provide a broad overview of the many 
challenges facing the cardiovascular device industry and the organizations involved. 
These accounts also illustrate the importance and value of engineering design principles 
and systems based engineering management in the industry. 
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INTRODUCTION TO THE INDUSTRY 
The cardiovascular device industry is, not unlike many other industries, in a 
slower than normal growth state as compared to figures over the past decade. With the 
regulatory burden continuing to increase and increasing pressures to reduce costs, the 
industry faces a significant number of challenges in the immediate future. Capital is now 
more difficult to come by than it has been in the past, therefore the number of successful 
startup companies has been limited. Pricing pressures continue to increase forcing 
companies to search for creative ways to market their products. In the face of all these 
pressures however, the demand for improved cardiovascular devices is unchanged.   
According to a 2011 report from the American Heart Association (AHA), 
Cardiovascular Disease (CVD) accounted for 406,351 deaths in the United States in 
2007; that figure equates to roughly 1 of every 6 deaths for the year. The report also 
estimated a cost of $286 Billion related to CVD and stroke in the United States. While 
new medical devices such as Ventricular Assist Devices (VADs) and Cardiac Rhythm 
Management (CRM) units have improved patient outcomes over the recent past, these 
devices are certainly not without their problems. There remains an unmet need for novel 
solutions for the treatment of heart failure. 
  
 2 
 
 
ABOUT CORINNOVA 
CorInnova Inc. is an early stage medical device company with a focus in device-
based therapies for congestive heart failure. Founded in 2004 by Dr. John Criscione, 
Biomedical Engineering professor at Texas A&M University, CorInnova is developing a 
cardiac assist device and is currently in the early stages of product development. The 
company utilizes fully patented cardiac assist technology and is seeking further patents 
for other intellectual property. Mr. William Altman serves as Chief Executive Officer 
and is charged with developing the company’s business strategy, building a team, and 
raising venture capital funds while Dr. Criscione serves as Chief Technology Officer 
overseeing product development and preclinical testing while maintaining involvement 
in all other aspects of the business. With just a handful of engineers working for the 
company, CorInnova seeks to introduce an innovative product to a highly complex and 
increasingly competitive cardiovascular assist device market.  
With an early startup company, there is usually a great deal work to be done and 
not nearly enough people to accomplish it. From a strategic standpoint, the company was 
and continues to develop a portfolio of intellectual property centered around unique 
interventions for congestive heart failure. In an industry which has seen significant 
reductions in investment dollars, this puts CorInnova in a challenging position. The 
drastic differences between the company's unique therapeutic approach and those which 
have become more common practice both set the company apart from competitors and 
present a high level of risk due to regulatory uncertainties and inevitably large costs for 
human trials. Nevertheless,  the therapy has produced promising results from animal 
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studies, and a number of advantages over current treatments put the company in a 
competitive position. The heart assist device which the therapy centers around can 
however use some improvement before. These improvements would serve both to 
expand the company's limited portfolio as well as present more attractive treatment 
technologies. 
Market Overview 
 
As the condition of patients with congestive heart failure worsens, the number of 
treatment options becomes more limited. In recent years, ventricular assist devices have 
gained traction, largely improving over first generation devices which featured a large 
number of moving parts which led to a high rate of mechanical failure. In addition to 
VADs, there are also multiple total artificial heart (TAH) devices available in the clinical 
environment with the CardioWest device from Syncardia having FDA approval as a 
bridge to transplant therapy. As discussed, these therapies are not without their 
limitations and improvements can certainly be made. A common feature between VADs 
and TAHs is that both devices are in direct contact with the patient's blood. VADs 
supplement the heart's ability to pump blood by pumping blood in parallel through 
inflow and outflow cannulas in peristaltic and continuous flow. TAH's require complete 
removal of the patient's failing heart and are directly linked to the patients' vena cava, 
pulmonary vein and artery, and the aorta. For both of these major treatment 
interventions, patients are administered potent anticoagulation drugs which reduce the 
risk of the patient forming blood clots in response to contact with the implant. These 
anti-clotting therapies can however lead to problems with forming clots at other 
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locations where they are needed. In the case of VADs that utilize continuous flow pumps 
there is even evidence linking the treatment to the formation of clotting disorders 
(Nicolini & Gherli 2009) 
VADs and TAHs are viable alternatives for patients at end stage heart failure, but 
other less drastic alternatives are gaining in popularity. Cardiac rhythm therapy (CRT) 
has quickly emerged as a very effective treatment for patients suffering heart failure. By 
pacing the atrium and ventricles in a synchronized rhythm, cardiac output can be 
drastically improved and has even led to cardiac remodeling in some many cases such as 
shown by Solomon et al. in Circulation (Solomon et al. 2010). The impact of CRT on 
overall function however seems to lower as the patient reaches more advanced disease 
states. These patients often have to turn toward other alternatives.  Notwithstanding this 
limitation, CRM therapy is quickly becoming a first line of treatment in the long struggle 
against congestive heart failure. (Nicolini & Gherli 2009)  
With most of the treatments and interventions discussed designed primarily to 
help slow the progression or compensate for the effects of congestive heart failure, it is 
important to consider the growing evidence of the heart’s ability to remodel itself and 
improve cardiac output in response to cardiac support treatment. As evident in the 
previously mentioned Solomen et al. study for CRT, other therapies have seen similar 
results. While the exact mechanism responsible for reverse remodeling is not well 
understood, the key device attribute common to the phenomena is temporarily reducing 
the load on cardiac muscle then following this support period with a gradual increase in 
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load until the support device can be removed completely thereby putting the complete 
load on the natural cardiac tissue. CorInnova’s support therapy is largely based on the 
reverse remodeling phenomena. In contracts to VADs however, the CorInnova device 
features some key differences in design. The most prominent difference stems from the 
fact that the CorInnova device is not in contact with the patient’s blood stream. Instead 
the device supports the heart from the outside of the heart. Before reviewing the design 
further, I thought it worthwhile to consider the problem in a more systematic form as 
commonly done in product development cycles. 
Customer Needs 
 
The first step in product development is generating a list of key customer 
requirements. Therefore using information collected from market research and clinical 
research we can clarify the important customer needs in both a clinical sense as well as a 
patient impact sense. We will first consider the clinical need. Cardiac output is a key 
measure of cardiac function and can be calculated as:  
C.O. = S.V. x H.R. 
where S.V. stands for stroke volume and H.R. stands for heart rate. The common CO 
observed in healthy patients is typically 5-6 liters/minute but in congestive heart failure 
these numbers can reach figures as low as 3 liters/minute in patients with congestive 
heart failure. The requirement to increase cardiac output for CHF patients is critical to 
improving patient conditions and quality of life. One challenge this requirement presents 
is that increasing cardiac output would put a large strain on heart muscle tissue, 
 6 
 
 
myocardium. These cells are responsible for their individual contraction and as when 
aggregated the contraction of the 4 heart chambers the Right Atrium, Right Ventricle, 
Left Atrium, and Left Ventricle. With the limitation of cardiac output directly linked to 
the limited ability of myocardium to undertake increased pump loads, the device must 
increase cardiac output while also decreasing workload on myocardium. In close relation 
to these two requirements is the atrium and ventricle chamber contraction synchrony 
must also be enhanced, thereby improving the movement of blood between the 
chambers, hemodynamics. With atrial and ventricular contractions out of sync, the 
workload undertaken by myocardium would increase dramatically and leave cardiac 
output unchanged or even reduced.  
While increasing cardiac output is a reasonably obvious need, it is worthwhile to 
consider the broader reason for this requirement. A brief statement describing the 
function of the heart can help in this respect. The heart is the body’s blood pump which 
delivers blood to throughout the body which in turn delivers oxygen to the tissue while 
removing carbon dioxide through capillaries. The heart’s right chambers also deliver 
blood to the lung capillaries in which carbon dioxide is removed from blood and oxygen 
is taken up by hemoglobin cells in the blood. In order to drive the delivery of blood to 
throughout the body, sufficient systemic blood pressure is required to improve tissue 
perfusion to firstly vital organs such as the brain and kidneys, and secondly to the rest of 
the body. Proper perfusion throughout the body would improve tissue oxygenation 
throughout allowing the patient to perform such seemingly trivial tasks as walking up 
and down the hall or sitting up in bed without placing a large strain on the body. Finally, 
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the patients’ safety should always be considered top priority and the level of risk 
associated with the treatment device must justify its utilization. Therefore the risk of life 
threatening blood clotting must be limited on one hand but the risk of excessive bleeding 
must be limited on the other.  
From a patient perspective, there are a few things to consider in addition to the 
clinical needs required to improve their medical condition. The invasiveness of the 
implant and procedure must be limited for one. The less invasive the surgery, the better 
chances the patient has of surviving the operation itself and the more attractive the 
device becomes to the patient receiving the implant and the physician implanting it. 
Recognizing the large portion of these patients in need of a bridge to transplant therapy, 
two things are considered. Most obviously, there must be an explants procedure which 
must also be limited in invasiveness as much as possible. But a more subtle requirement 
is that the therapy must not risk the patient eligibility for a heart transplant. This further 
emphasizes the need to balance clotting and bleeding risks since any adverse event of 
that nature could compromise the patient’s eligibility status. Patients and their families 
seek options that not only improve their state of health but also improve their overall 
quality of life, allowing them to resume a more normal lifestyle. So in addition to the 
clinical benefits, the system should also allow for patient mobility within the hospital 
and even outside the barriers of the hospital or a home care environment. Finally, there is 
a wide range in age and size within the patient population and therefore the system must 
be scalable to some extent to address limited implant real estate and the like. 
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From a more system approach and with consideration of the principal of reverse 
remodeling, the treatment system must allow for adjustable support. This would allow 
physicians the ability to fine tune support systems to maximally improve their patient’s 
condition and after appropriate periods improved condition, follow up with a reduction 
in support. Even after the system is initially tuned to the patients needs, the level of 
support required can change either progressively or rapidly, therefore the system must 
have some intrinsic ability to automatically detect altered patient physical state and 
adjust its output appropriately. Finally, the proposed system must limit its power 
requirement to a level sustainable within a typical hospital room setting and, in light of 
the patient mobility need, sustainable for a reasonably sized battery. 
Therefore in light of the needs discussed, we conclude with the customer 
requirements list as shown in Table 1. 
 
Table 1. Customer Needs List. 
Category Description of Need 
Clinical Improve cardiac output (S.V. x H.R.) 
Clinical Decrease work load on myocardium.  
Clinical 
Improve synchrony of chamber contraction and thereby 
hemodynamics 
Clinical  
Improve systemic pressure & thereby tissue perfusion throughout 
body 
Clinical Keep Patient's heart transplant eligibility uncompromised.  
Clinical Keep patient free from risk as much as possible. 
Clinical/Patient Limit invasiveness of implant & explant procedures. 
Patient Allow for patient mobility. 
Patient Allow patient to resume a more normal lifestyle 
Patient/System Scalability of system size 
System Allow adjustment and variability of support output 
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Table 1. Continued. 
Category Description of Need 
System Respond to patient needs and changes in need 
System Limit the external power requirement to support device function 
 
Function Set 
 
With our list of customer requirements generated, we now move to a functional 
approach through which we convert the customer requirements to a set of possible 
functions to utilize in order to address these customer requirements. A further analysis of 
the links between these functions and the customer needs is necessary but we must first 
identify a comprehensive set of functions which the design could utilize. The functions 
and system characteristics as listed in Table 2 are considered: 
 
Table 2. Function/Characteristics of Design. 
To Address Fundamental 
System Requirements 
To Address Patient 
Requirements 
To Address System 
Requirements 
Pressure differential Size of implanted device 
Convert energy to pressure 
differential 
Synchrony with cardiac 
rhythm and hemodynamics Size of external subsystem 
Transfer pressure differential 
to patient heart 
Detection of atrial and 
ventricular contraction Size of delivery mechanism 
Alert patient of malfunction 
or damage 
Post-ventricular blood 
pressure 
Internal and external battery 
sizes 
 Measurement of systemic 
oxygenation demand Size of whole system 
 
 
Steps required during 
operation 
 
 Scalability of system  
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With this list of functions, I could move forward with a deeper analysis of the 
relationships between the customer needs and the device functions listed. To accomplish 
this task, I utilized traditional quality function deployment (QFD) technique as 
commonly applied in product development processes. 
Quality Function Deployment 
 
Before going over the QFD for this device, I felt it worthwhile to review the 
purpose and value of performing a QFD. A quality function deployment is a design tool 
used to both identify and quantify the relationships between system functions and the 
more generalized customer requirements. The calculations made in QFDs allow for the 
quantification of how different design functions align with or do not align with customer 
requirements. Additionally with as multiple design functions are linked to single 
customer requirements, a QFD can identify whether the design functions are in conflict, 
are in line with each other, or have no impact on each other. This clear identification and 
the quantification of key design elements allow for balancing the system design. 
Additionally some QFDs even consider competitive technologies and thereby help 
identify opportunities for novel approaches and solutions. Therefore the value of QFD 
can bring to the design process is considerable and well worth the effort especially for 
complex design undertakings such as cardiac support devices. 
I started my QFD process with the competitive analysis using traditional 
ventricular assist devices, total artificial hearts, and cardiac rhythm management 
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therapies as the competitors. Figure 1 summarizes this analysis with respect to the 
defined user requirements. 
 
 
Figure 1. QFD – Competitive Analysis 
 
The QFD allows for prioritizing customer requirements as well and for this 
competitive analysis segment, allows for identifying opportunities in the competitive 
landscape. Without going into a great deal of detail, we can see that while competitive 
therapies can address cardiac output and load reduction requirements, the risk to the 
patient for clotting or bleeding complications tends to increase. The advantage of 
significantly limiting the risk of clotting and bleeding through the fact that CorInnova’s 
device does not come into contact with the patient’s blood stream rather it delivers 
support while remaining external to the heart. Another disadvantage of the competitive 
solutions is that current technologies keep patients significantly limited in their ability to 
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be mobile and live normal lives. Most VADs require percutaneous lines which keep 
patients tethered to external control systems. The same holds true for artificial heart 
solutions. For this design problem the patients considered would face later stages of 
heart failure and therefore CRT does not score well in most of the requirements listed 
with the exception of improving synchrony. Therefore the opportunities in the 
competitive landscape present themselves around limited complication risk therapies 
which allow significant patient mobility. I continued with the functional relationships 
with the customer requirements. This is a bit more involved so I will not describe every 
detail but rather focus on more general observations.  
A number of observations can be made in this section of the QFD. The 
relationship between our customer requirements and the functions listed as shown in 
Figure 2, allows us to generate a relative requirement weight for each of the functions or 
design aspects considered. We see that the conversion of energy to a pressure differential 
is the design aspect with the highest weight while transferring the pressure differential to 
the heart is a close second. Synchronizing the heart, increasing post-ventricular pressure, 
and the pressure differential itself were not unsurprisingly high in weight the steps 
required during operation and the internal battery size were of small weight by 
comparison.  
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Figure 2. QFD – Functional Relationships with Customer Requirements. 
 
The final portion of the quality function deployment is commonly referred to as 
the roof and it characterizes the correlations between the design functions and 
characteristics. Figure 3 illustrates the contents of the so called roof for our design 
problem in table form. 
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Figure 3. QFD – Cross-Functional Interactions. 
 
Here we can see that the transfer of differential pressure to the patient heart has a 
large amount of correlations, making this design aspect crucial for the success of the 
overall product design. Detecting atrial and ventricular contractions, the size of the 
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implanted device, and the conversion of energy to the pressure differential also have a 
number of correlations with other design aspects. 
After applying the QFD method to CorInnova’s design challenge, a number of 
key design functions were identified one of which I would investigate in greater detail. 
The fundamental customer requirement key for both setting the therapy apart and 
improving market interest and general reception of such a different and unique therapy 
was the requirement to allow for patient mobility and a lifestyle closer to normal.  
Sub-System Design 
 
The CorInnova device would need to offer a fully implantable system with 
external power support or battery packs as needed. In light of the inefficiencies of 
transcutaneous energy transfer systems, the system would limit its utilization of TETS 
technology for direct pressure driving purposes as is common in other fully implantable 
approaches. For initial acute animal studies, the proposed system would have 2 
subsystems, one to be implanted and partially in direct contact with the epicardium or 
the outer tissue of the heart, and the other to be external to the patient but linked to the 
internal system through a proprietary transcutaneous driver system. While the driver 
system design addresses the function of driving a pressure differential, there is one key 
function missing. That is the function of measuring and detecting the natural rhythm of 
the heart is left ill-defined. As shown in our QFD, the detection of the natural heart 
rhythm is essential for providing dynamic support which is also in synchrony with the 
patient intrinsic pacing mechanisms. Therefore to ensure the system works with the 
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patient’s heart and not against it, there needs to be a system for measuring the natural 
rhythm and communicating this rhythm with the main pressure driver – the external 
subsystem. With a strict elimination of any percutaneous wiring or tubing, the signal 
would have to be communicated wirelessly. Surface ECGs were briefly considered but 
the significant level of interference from electro-myogram potentials (EMG) would lead 
to possible misrepresentations, leading to over-stimulation or inactivation when required.  
The proposed system would therefore take advantage of stronger signals 
measured at the epicardium. These signals would be free of EMG interference and not as 
vulnerable to surface electrode placement and movement related errors as is a concern in 
moving patients. The system would also communicate an appropriate trigger signal to 
the external pressure driver in a manner sufficient as to allow the driver to activate and 
transfer the pressure to pressure cuff placed around the heart, thus supporting heart pump 
function in a synchronous fashion. In simple terms, the system would have to detect and 
send a signal for the beginning of the heart beat in time for the pressure driver to receive 
the signal and apply the pressure back inside the patient when the ventricle begins to 
contract or just thereafter.  
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Figure 4. Wiggers Diagram 
*Reprinted from “Wiggers Diagram.png” by Daniel Chang, MD, 
DestinyQX, and xavax, 2012. Wikipedia, Copyright 2012 by 
Creative Commons 
 
 
To get a better understanding for the timing requirement, let us review the 
electromechanical aspects of the heart. One very useful tool first which I was first 
introduced to in a Cardiac Mechanics course is the Wiggers diagram such as shown in 
Figure 4. The ECG is a very useful measure of the electrical activity in the heart, but 
with the heart being an electromechanical system the ECG also holds a great deal of 
mechanical information. A normal cardiac cycle begins with atrial contraction which 
starts with an electrical action potential at the sinoatrial node located at the top of the 
right atrium. As the signal propagates in the atrium along the myocardium, the atrial 
chamber contracts, first increasing pressure within the atrium and then forcing the valve 
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open between the atrium and ventricle, delivering blood into the ventricle. As this is 
happening the electrical signal makes its way to the atrioventricular node which slows 
the signal allowing the atrium to eject blood into the ventricles. Then the signal 
continues to propagate into first the bundle branches along the septum or the inner 
ventricular wall, then spreading through the Perkinje fibers to the outer walls of the 
ventricles. While the electrical signal starts near the right atrium it is carried to the left 
atrium through Bachmann’s bundle and to the left ventricle through the left bundle 
branches. Although slightly delayed in relation to the right atrium and right ventricle, the 
left atrium and left ventricle follow the same contraction pattern.  
The Wiggers diagram illustrates the interrelationship between ECG propagation 
and atrial and ventricular contractions by plotting the pressure inside the left ventricle, 
the left atrium, and the aorta. Chamber volumes are also plotted along with a plot of the 
audible sound of valves closing in some cases such as in the one shown in figure. 
Looking at a typical 60 beat per minute ECG signal, the start of atrial contraction as 
denoted by the start of the P-wave and the start of ventricular contraction as signaled by 
the beginning of the R peak in the QRS segment complex are only separated by roughly 
120-200 ms. This small window is the maximum time which our system can take to 
detect the p-wave, transmit the trigger signal, receive the trigger signal at the pressure 
driver, and apply the pressure differential at the epicedium through the pressure cuff.  
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Functional Breakdown 
 
The function of the ECG trigger mechanism as proposed can be broken into three 
high level functions. The subsystem must detect the action potential at the SA node, 
transmit the trigger signal, and receive the signal at the external driver control 
subsystem. Detecting the action potential can be accomplished in a fairly straightforward 
way using a sensor or electrical lead, and an analog circuit to detect the voltage 
differential between the lead placed near the SA node and some other reference point 
such as another lead at the apex of the pressure cuff. The analog measurement can be 
taken by differential amplifiers, however, because of the small scale differences in 
potential, specialized operational amplifiers are often utilized in ECG applications. 
Typically, ECG signal amplitudes are in the single mV range with a typical DC offset 
two to three magnitudes higher. Luckily, there are a number of operational amplifiers 
with characteristics tuned specifically for such signal detection.  
The second function of transferring a trigger signal wirelessly presents three 
challenges. First the analog signal coming from the AFE needs to be digitized. After the 
digital signal is encoded in the chosen format, the signal must then be passed to a 
wireless communication circuit which then sends the wireless signal. The signal is then 
received, decoded, and relayed to the pressure activation control circuit. With 
advancements in radiofrequency technologies, there are RF transceiver chips now 
available which can encode, transmit, and receive RF signals. The added challenge in 
our case is the fact that the transmitting chip will actually be implanted into the patient. 
The RF signal must then be able to penetrate the patient’s tissue and do so in a manner 
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that does not put the patient at risk from overheating but also does not risk the integrity 
of the signal. 
As mentioned above, the analog signal must be digitized. This digital conversion 
is commonly accomplished by microcontrollers with embedded analog to digital 
converters. The microcontroller must be programmed to interpret the analog signal 
appropriately, thereby producing the preferred digital signal to be relayed to the 
communication circuit or chip.  
Finally, with all functions accounted for through the AFE, the microcontroller, 
and the transceiver chips, the components must be interconnected into one system. The 
function of integrating these components can be accomplished through the use of smart 
boards which provide a hardware platform on which to interconnect the functional 
components. Smart boards also manage power consumption which in our case would 
come from an internal battery source.  
Limitations 
 
The proposed design approach is feasible and, through the utilization of standard 
communication protocols and commercially available components, can be relatively in-
expense to create. However, the application of the proposed system being of life-
threatening nature, would almost certainly require a continuous RF signal to be 
transmitted. This requirement would be a tremendous limitation to the life of the 
implanted system. Therefore a recharging system would be essential for long-term 
applications. While a limited life system would be sufficient for acute animal studies, a 
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recharging mechanism or a different approach altogether would be necessary for a 
human implant application. Recharging circuits direct our attention back to TETS 
technologies which we were trying to avoid. However, when we compare the use of 
TETS in our design approach versus that of many other fully implantable approaches, 
there is a significant difference in our use. With our approach, the pressure driving 
circuit remains outside of the patient, therefore the TETS system would only be required 
to recharge the ECG trigger communication circuit rather than supporting the pressure 
driving circuit as well. This system would consume much less power than a complete 
support system. So although we cannot fully abandon TETS technology, the way in 
which we apply it places this inefficient technology in a much lower risk area. Thus our 
application decouples it from the primary device objective of applying pressure to the 
heart. 
Though plans were in place to move forward with a prototype, the battery life 
limitation and the complexity of the system along with the consideration of our limited 
experience in this type of application, CorInnova was led to consider different solutions 
which are still under investigation. Unfortunately, my experience at CorInnova was cut 
short of my originally planned duration when an opportunity to work with a more 
established and experienced company presented itself. Given the uncertainties 
surrounding the future of such a young company, I made the decision to work for 
Biotronik, a leading company in the cardiac rhythm management market. 
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ABOUT BIOTRONIK 
  Biotronik is one of the leading manufacturers of electronically active implants for 
the cardiovascular field. Considered among the top competitors, Biotronik continues to 
gain market shares in Europe as well as in the United States. One notable difference at 
Biotronik is that the company is privately owned as opposed to the publically traded 
companies at the top of the list such as Medtronic, St. Jude Medical, and Boston 
Scientific. While capital may be limited at times for the low key company, its private 
ownership allows flexibility unmatched by any publically traded organization. Led by 
the visionary leadership of Dr. Max Schaldach, son of co-founder Max Schaldach, the 
company has continued to deliver high quality devices for over 30 years, pioneering key 
innovations such as fractal coating which was considered a breakthrough in lead 
performance.  
Although small with just over 5000 employees worldwide, Biotronik is 
represented in over 100 countries. With a vertically integrated approach to product 
development, Biotronik has subsidiaries manufacturing device components such as 
leads, batteries, and headers as well as the complex electronic modules which device 
output. The modules development takes place in two key manufacturing and 
development centers. One is located in Berlin, Germany and is directly linked to the 
worldwide headquarters while the other is located in Lake Oswego, Oregon and forms 
the subsidiary company of Micro Systems Engineering, Inc (MSEI). All device 
components are shipped to Berlin, where final product assembly takes place, however a 
large portion of the development takes place right here in the United States.  
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Although, Biotronik and its subsidiaries have a great deal of flexibility regarding 
vision and leadership, the same regulations for both for both the financial and clinical 
aspects apply as they do for the larger corporations. For MSEI in particular, in the 
financial realm accountants and financial controllers ensure the company follows 
generally accepted accounting principles (GAP) and reports their annual income on 
which they pay taxes to the internal revenue service (IRS). In the clinical and device 
design functions, MSEI must also comply with regulatory requirements such as 
requirements from the FDA or the European Commission to get products out to market. 
With electronically active implantable medical devices of the CRM nature having such 
direct impact on the life-sustaining function of the heart, CRM devices are considered 
Class III medical devices by the FDA and Class A medical devices by the EU. These 
classes of medical devices face the utmost scrutiny and the bar continues to be raised in 
an effort to ensure the quality of the devices making it to market and being implanted in 
patients.  
For engineering design, the key regulatory requirement is to establish a quality 
system in compliance with 21CFR820 for FDA compliance and ISO 13485 for EU 
compliance. The primary impact on design is the requirement to set and continually 
follow appropriate design controls from initial market needs definition all the way 
through to the first product sale in the clinical field.  
For many medical device companies the responsibility of ensuring product 
design efforts follow the appropriate processes falls to the design team for each of their 
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respective areas of concentration and to program managers who ensure the aggregate 
design effort for the product as a whole is in compliance with the established policies. 
Quality however is just one aspect of program management. Additionally program 
managers (PMs) are responsible for driving the design effort, projecting costs along the 
way, solving technical problems that arise and finally controlling design project 
outcomes and costs. With an incredible portion of product costs stemming from the 
design effort costs which are spent long before the first product sale, it is vital that 
projects come within budget and, of equal importance, within schedule. The final 
responsibility of PM is to ensure that the final product design meets customer needs as 
defined by the customer requirement scope. With the length and complexity of meeting 
scope requirements directly linked to the duration and cost of the design effort required, 
PMs have to balance the set of requirements with the schedule and available resources to 
ensure all stakeholders are satisfied and confident in the product feature set. PMs are 
those responsible for ensuring the design effort meets the established customer 
requirements, the established control policies and the estimates cost and schedule targets.  
For single projects, these functions are exactly those of a project manager. When 
these responsibilities extend across multiple projects often sharing resources (equipment, 
dollars, and staff) it is considered program management according to the Program 
Management Book of Knowledge printed by the Program Management Institute. 
With MSEI involved in a number of such complex product design efforts, the 
program management office is vital to the success of the organization both within MSEI 
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and extending to the Biotronik family of companies altogether. With program 
management so closely related to company spending in R&D company, as most R&D 
company spending revolves around the product development efforts. It is only natural 
that the PM team also be responsible for established the overall budget for the 
foreseeable future. Hence, MSEI formed the Budget & Program Management team 
which consisted of four highly experienced and knowledgeable engineers directed by the 
department’s director, Andreas Gute. 
Problem Statement 
 
I was lucky enough the join the Budget and Program management team as an 
intern and was given information regarding a number of possible internship projects 
from which to pursue. One particularly caught my interest partly because it seemed to 
compliment my knowledge and experience very well. In addition to the aligned interests, 
this project was given high priority with direct visibility for senior management. With 
such high visibility and such high impact on the organization it was given first priority. 
To better understand the nature of the problem let us review the basic problem 
definition. In simple terms the integration between program management and financial 
management software systems was poor. This forced a number of inconsistencies 
between financial reports and program management reports, which forced many 
complex reports to be manually created using information from a number of sources. 
Not surprisingly, there were often mistakes in data entry due in large part to the heavy 
use of manual data input. These mistakes forced accounting and financial controlling 
staff to spend a large amount of their time to make sense of input from all these sources 
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and tracking down any inconsistencies. While the problem persists in many areas, the 
most crucial problem was observed in its impact on the program cost forecast and the 
financial forecast for the entire MSEI company.  
In light of this fact, it quickly became apparent why the project was given such 
high priority. As a subsidiary of an international organization, not unlike most 
subsidiaries, MSEI must come up with a forecast of future costs which then determine 
their annual budget after senior management review and approval. As miscue in these 
figures could lead to mistakes in budget setting, therefore any and all measures, 
including many hours of tracking down inconsistencies, were taken to ensure the 
accuracy of the numbers requested.  
Root Cause Analysis 
 
My first step was to find the root cause of possible errors and I was lucky enough 
to find an example of freshly observed errors having been pointed out the week before 
my internship started. The problem observed was simply that financial report figures and 
PM system report figures were not matching up. I was to figure out why there were not 
matching up and resolve the problem within a few weeks to ensure proper budget entry 
reporting for the coming budget request cycle. For financial and accounting questions, I 
had my finance team, for program management questions I had my department, and for 
technical questions, I had support staff from our program management software system 
as well as for our financial software system. I would start by comparing the two reports 
 27 
 
 
which were labeled as inconsistent and checking whether there were true errors or the 
problem stemmed from miscommunication or data.  
A closer look at the nature of these reports revealed a few key reporting practices 
which could account for part of the misunderstanding. The financial report which I’ll 
refer to as Report A consisted of a list of active projects for which actual costs and/or 
forecasted costs exist which are expected to be spent before year end. With the numbers 
not clearly separated for spend versus future estimate, it could not be distinguished how 
much had already been spent with Report A alone. The program management report 
which I’ll refer to as Report B was a comprehensive report of all program management 
budget entries for all projects under the entire program management software system. 
Therefore Report B had much more detail than Report A, but the totals reported in 
Report B for all projects was expected to match the totals reported for Report A. This 
was not the case however.  
The information that was entered into Report A was the responsibility of our 
accounting and financial controlling staff. As with any other major financial reports, this 
data was carefully collected and quite often took several days, if not weeks, of work to 
compile. I spent a large amount of time with our accounting staff to better understand 
their input and the work it took to get this data. As expected there was no flaw in the 
final results of their data collection, though the nature of their process to gather the 
numbers was inconsistent and quite often highly inefficient. Actual costs were collected 
directly from the financial system and could be identified to each of the projects for 
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which they were incurred. Forecasted costs on the other hand were collected from the 
MSEI program management staff in the form of a number of spreadsheets. This process 
seemed fairly simple and was only complicated in cases where program managers made 
last minute changes to their forecast. The addition of the program management system 
however quickly complicates matters.  
The program management system utilized at MSEI is the system used throughout 
the Biotronik product development and manufacturing entities. It is a robust system 
which supports a large number of users spread throughout the world, and it is used not 
only for project timelines and cost planning, but also for employee time reporting 
throughout Biotronik. While the system features a large number of capabilities in its own 
right, the system must also be interconnected with the financial system for functions 
such as purchasing material against a project or charging employee labor costs to the 
project. With respect to the forecast report, Report B, it is based on a report template 
which pulls cost information from the entire system database which includes all active 
projects in the system. The data is collected directly from the program planning tools 
which is where PM staff update project schedules and expense projections. To identify 
company specific expenses such as those for MSEI, an organization code is included in 
the report. Finally, the report makes one very important assumption. That is the report 
assumes PM staff update the planning on a monthly basis including the reconciliation of 
actual costs in the planning tool. This assumption very quickly raised a red flag in my 
review and it quickly became apparent that the assumption was in most cases incorrect.  
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Therefore with the assumed actual expenses in Report B not equaling the actual 
expenses incurred through the financial system included in Report A, the two reports 
would simply never agree with each other. With the reconciliation of actual costs in the 
planner placing such a considerable burden PM staff for reasons beyond the scope of my 
project, the cause was communicated to senior management and the limitation was 
accepted. Therefore actual costs and forecasted costs would be separated in Report A 
and it would be understood that only the forecast numbers from Report A and Report B 
would be consistent.  
While this revelation accounted for some of the smaller scale differences 
between report numbers there was still a large number discrepancy between the two 
reports, with Report A totals being considerably higher than Report B totals. Our finance 
team soon revealed the exclusion of administrative or overhead expenses in the program 
management system. With the PM system viewed as a purely project related system, it 
was assumed that overhead expenses would be omitted from the system. To make up for 
the large discrepancy, it was quickly decided that overhead expenses be included in the 
PM system for the sake of consistency across financial and program management system 
forecast figures.  
With the root causes of the observed inconsistencies identified and a clear plan in 
place for the immediate forecast cycle, my short term objective was successfully 
completed, though my work was just getting started.  
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Automation of Data Transfer 
 
The next undertaking would be to automate the transfer of forecast data from the 
PM software system to the financial software system. I again gathered insight from each 
of the parties at my disposal and mapped the flow of information between systems. I was 
quickly reminded of the large amount of manual data entry throughout the process which 
reiterated the importance of automating the data transfer between the systems. Figure 5 
below illustrates the flow of information required to put together a comprehensive 
budget for MSEI. This particular view shows a clear separation between the software 
systems utilized including the financial and program management systems but also a 
number of MS excel spreadsheets.  
 
 
Figure 5. Data Flow Diagram. 
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Starting with the excel spreadsheets containing project related expenses, these 
provide data to be entered into the program management system as well as the data to be 
entered in the financial system and Report A. In the PM system the data was entered in 
the planning tools for the affected projects while in the financial system, the data was 
entered in the affected cost accounts. Once this data is entered in the program 
management system, the project expense forecast would then show up in Report B. For 
the administrative related expense forecast, the data comes from the financial system 
since the forecast is largely based on incurred expenses during previous periods. Prior to 
the decision of including administrative expense forecasts in the program management 
system, the data related to these administrative costs was only entered directly into 
Report A. Lastly, actual expenses as shown in the financial system would be entered into 
Report A, but would not in the planner tool within the PM system. The proposed 
changes to the data flow would include administrative related forecasts in the PM system 
and as a measure toward eliminating error all forecast data included in the Report A 
would originate from the PM System. This would assure that the forecast figures shown 
in Report A would match the forecast figures in the PM system and as shown in Report 
B. For the actual costs, it was understood and accepted for the time being that they 
would not be reconciled in the PM system and therefore would not match the numbers 
from Report A. To further illustrate this point and to provide additional information, the 
actual costs and the forecasted costs would be separated in Report A. After these 
changes were implemented, the data flow would change to that shown in figure 6. With 
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an agreed upon plan in place, the technical work could begin toward forming a working 
automation solution.  
 
 
Figure 6. Improved Data Flow Diagram. 
 
 
For the automation of data transfer, a number of solutions were considered as 
shown in the Table 3 below. The solutions considered can be described as follows: 
1. Using an intermediate MS Access database and a few report variants to pass 
data between the systems 
 
2. Using MS Excel VB scripting coupled with PM system reports to generate 
files that can be imported into the financial system 
 
3. Using a 3rd party system integration tool to pass data between the two 
systems automatically 
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4.  Using system integration tools built in to the existing systems to set up direct 
communication between the two.  
 
 
 Table 3. Decision Matrix 
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Read data from source 3 3 3 4 5 
Interpret data 5 5 5 5 5 
Calculate data 5 5 5 5 5 
Deliver data to 
destination 3 3 3 4 4 
Ease of Use 3 2 4 4 5 
Resources required 5 3 5 1 1 
Maintenance 5 1 4 1 1 
Complexity 4 2 5 1 2 
 Total Score 
 
102 145 100 110 
 
 
Largely due to its small level of resource requirements, maintenance, and 
complexity level as compared to the other solutions, the solution based on Excel Visual 
Basic Script was chosen for its simplicity and low maintenance nature. Programming the 
systems to communicate directly was a close second but its heavy resource requirements 
and the likely maintenance costs made it less attractive.  
With the approach decided upon, my next step in creating a solution was to break 
up the programming requirements into the major coding functions required to deliver the 
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required output. This high level breakdown shown in Figure 7 would serve as an outline 
for code development. 
 
Figure 7. High Level Breakdown of Script Functions. 
 
As used to compare the functional advantages for each of the solutions 
considered, the function of the script can be broken into the three sections of opening 
and scanning the input, calculating the output, and then delivering the output in a usable 
form. For the first section, the script was to open and scan the source data then generate 
a list of unique projects included in the source data since the number of lines per project 
varied. After the initial scan of the data, our calculations could then take place first 
calculating a Forecast Detail array then out of this calculation continuing with a 
calculation of a data array for the Report A input and an array of financial system data to 
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be imported into it. Finally to deliver the data to each of their destinations, the data for 
Report A could be inserted directly while the data to be imported into the financial 
system would be saved in a format that could be imported into the financial system.  
Execution and Code Development 
 
In addition to the task of generating the code, there were a few supporting tasks 
that needed to take place that would have significant influences on the code. First a 
report with all of the relevant information for both Report A and the financial system 
input would need to be created in the PM system. This required coordination with the 
PM system technical support group to create an appropriate report template and 
coordination with the financial system support group to help define data needs. Based on 
the template utilized for Report B, the group was able to include month by month data 
spanning across the 24 months following the date of report generation which would 
cover the financial system’s requirement of month by month data for the following 18 
months at the end of each fiscal quarter. Another more administrative and process 
oriented was related to the way expense forecasts were entered into the PM system. With 
a description field in the PM system at our disposal, the script could take advantage of 
custom text to identify each department’s expenses without adding to the program 
manager’s project administration burden. Finally, the output file which was to be 
imported into the financial system would have to be formatted into an acceptable layout 
that could be properly interpreted by the financial system import toolset.  
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With the supporting tasks in place and under way, the process of writing the code 
to perform the functional requirements could also begin. However, the risk of changes to 
the supporting tasks and reports was mitigated by first addressing the functions with 
more definite input and output expectations. With the efficient handling of arrays in 
Excel VBS, virtually all subroutines and functions utilized arrays allowing the script an 
added advantage of minimized memory consumption even during large file runs. 
As the development of the code regarding the functional block for the financial 
system data came up a few questions surfaced. One was related to the financial system 
cost accounts as compared to the PM system cost types while the other was a bit more 
complex. The cost types in the two systems were not set up identically and as a result 
there were several accounts in the financial system which did not have clear equivalents 
in the PM system. This required some negotiating with our accountants as well as our 
PM staff to ensure there was a clear mapping of cost types between the PM system and 
the financial system. Thereby ensuring that financial system input would have a clear 
destination for all entries put into the PM system. After agreements were reached, I 
quickly wrote down the terms in a formal document and made it available for all PM and 
finance staff reference.   
After weeks of coding, a demonstration was schedule with the finance group and 
a few key enhancements were immediately requested. First, it became well apparent that 
there had to be a method for selecting the data document. The code had to be verified in 
different generations of software, at least one older and one newer generation. After a 
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few more weeks of coding, the next solution was ready for demonstration and with the 
coming budget cycle quickly approaching, it was ready just in time.  
Delivery 
 
The final version of the script, now embedded in the template file for Report A 
allowed the user to first select their data file, generated out of the PM system, from their 
file directory and an appropriate start date for the budget period being calculated. After a 
number of heavy array calculations and sub-functions, the forecast data would be 
inserted in the appropriate location in Report A and the user would be then be prompted 
to enter a filename for the output files to later be imported into the financial system. 
With great reception from our financial department and agreement from all PM staff 
regarding adjustments in their forecast entries, the final solution ensured consistency 
between forecast figures in the PM system, the financial system, and the data in Report 
A. Also just as importantly, the amount of time spent putting together this information 
went from several days to weeks of work to a few seconds it took the code to run. With a 
solution delivered and all supporting documentation including user instructions for script 
as well as PM system data entry, my internship project was complete.  
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CONCLUSION 
 This concludes the summary of my internship experiences with first CorInnova 
and then Micro Systems Engineering, Inc. a subsidiary of Biotronik. I feel very blessed 
to have had these experiences and am eternally grateful to those who have influenced me 
along the way. I feel confident that my contributions to these organizations were 
valuable and this would not be possible without the education and skills I gained at the 
Dwight Look College of Engineering and Mays Business school of Texas A&M 
University. In an industry full of engineering challenges and operational obstacles, I feel 
well prepared to be a valuable asset in the industry. The knowledge and experiences 
gained throughout my education and internships are and will always be invaluable.   
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